

April 15, 2025

To  <b>The Corporate Relations Department BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001  <b>Code: 540222</b>	To  <b>The Listing Department National Stock Exchange of India Ltd.,</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051  <b>Code: LAURUSLABS</b>
---	---

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir / madam,

Further to our intimation dated 31<sup>st</sup> January, 2025, on the inspection conducted by the United States Food & Drug Administration (USFDA) at our API manufacturing facility Unit-4, Atchutapuram, Anakapalli District (Visakhapatnam), Andhra Pradesh from 27<sup>th</sup> January, 2025 to 31<sup>st</sup> January, 2025, we are pleased to inform you that the Company has received the Establishment Inspection Report (EIR).

This is for your information and record.

Yours faithfully,

For **Laurus Labs Limited**

**G. Venkateswar Reddy**  
Company Secretary & Compliance Officer

**Registered Office**

Laurus Enclave, Plot Office 01, E. Bonangi Village,  
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

**T** +91 891 682 1101, 1102, **E** info@lauruslabs.com  
**F** +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

**Corporate Office**

2<sup>nd</sup> Floor, SDE Serene Chambers, Road No. 7,  
Banjara Hills, Hyderabad - 500034, Telangana, India.

**T** +91 40 6659 4333, 3980 4333, 2342 0500 / 501,  
**F** +91 40 6659 4320 / 3980 4320